Solution-phase manufacture of N-benzyloxycarbonyl-L-amino acids begins with N-(benzyloxycarbonyloxy)succinimide, CAS 13139-17-8, charged as a 1.05–1.20 molar equivalent relative to free amino groups in a two-phase dioxane/water system maintained at pH 8.0–9.0 by a pH-stat titrating 1.0 mol/L sodium carbonate. The amino acid is dissolved at 0.8–1.0 mol/L in the aqueous phase within a 500 L glass-lined reactor equipped with retreat-curve impeller agitation at 80–110 rpm. The Cbz-OSu stream is separately prepared as a 25–40% w/w solution in anhydrous dioxane or THF and dosed through a PTFE-lined lance below the liquid surface at 0–5 °C. Because hydrolysis of the succinimidyl carbonate accelerates above pH 10.0 and above the 10–12 °C thermal boundary, the pH-stat set point is biased to 8.5±0.2, and the jacket return temperature is not permitted to exceed 8 °C until HPLC indicates residual free amine below 0.5 area%. This pH window is the primary process conflict: aminolysis is fast enough above pH 7.8, while carbonate hydrolysis and benzyl alcohol generation become kinetically competitive above pH 9.5.

When HPLC monitoring confirms consumption of the starting amine, dioxane or THF is distilled under vacuum at ≤35 °C, and the concentrated aqueous phase is acidified to pH 2.0–2.5 with 4 mol/L hydrochloric acid. The protected amino acid is extracted twice with ethyl acetate, washed with 15% w/v sodium chloride to remove water-soluble N-hydroxysuccinimide, dried over magnesium sulfate, and concentrated. Crystallization from ethyl acetate/n-heptane yields the N-Cbz amino acid as a crystalline solid. Terminal products from this route include N-Cbz-L-valine, N-Cbz-L-phenylalanine, and N-Cbz-L-leucine, each isolated as a white to off-white crystalline powder with residual N-hydroxysuccinimide controlled to ≤0.5% by 1H NMR or ion chromatography. Compliance for registered peptide intermediate production falls under ICH Q7, with release limits commonly set at HPLC purity ≥98.0%, water ≤0.5% by Karl Fischer, and loss on drying ≤0.5% after double-cone rotary vacuum drying at 35–40 °C and ≤50 mbar.

The dominant operational incompatibility is contact with ammonia, primary amines, or secondary amines in the isolation area: even trace amine vapor can convert surface Cbz-OSu to benzyl carbamate and raise residual succinimide levels. For this reason, final product is sieved through a 500 μm sieve and packed into antistatic LDPE liners under nitrogen. A second boundary is posed by prolonged storage above 25 °C; under uncontrolled warehouse conditions above 30 °C, the crystalline reagent slowly releases benzyl alcohol and carbon dioxide, reducing assay and changing the stoichiometric charge in subsequent N-protection reactions.

How Does Cbz-OSu Function When Capping Side-Chain Amines in Solid-Phase Peptide Synthesis?

Boc/Bzl solid-phase peptide synthesis uses N-ε-Cbz-lysine as a standard orthogonal side-chain protected amino acid, and the monomer is frequently built in-house by treating α-Boc-lysine with Cbz-OSu before loading onto hydroxymethylphenylacetamidomethyl resin. In the monomer reactor, 1.2–1.5 molar equivalents of Cbz-OSu relative to the ε-amine are maintained in anhydrous DMF with 1.2–1.5 equivalents of N,N-diisopropylethylamine at 20–25 °C. Agitation continues for 6–12 h until the Kaiser test is negative; the mixture is then concentrated under high vacuum at 35 °C to remove DMF. The crude N-α-Boc-N-ε-Cbz-L-lysine is partitioned between ethyl acetate and 5% w/v citric acid, washed with water, and crystallized from ethyl acetate/n-heptane. HPLC purity for release is ≥98.0%, with residual DMF controlled to ≤0.1% by headspace GC and palladium limited to ≤10 ppm when the Cbz group is later removed by catalytic hydrogenolysis.

On solid support, Cbz-OSu is less commonly used for routine α-amine capping because the benzyl carbamate is not removed by the trifluoroacetic acid deprotection step in Boc chemistry. Its primary solid-phase role is monomer-level side-chain protection of lysine, or selective blocking of exposed amino groups in resin-bound amino-terminal fragments before subsequent side-chain manipulations. The operational boundary is the same as in solution: piperidine, used in Fmoc deprotection, cannot be present in any vessel receiving Cbz-OSu because immediate aminolysis produces benzyl piperidyl carbamate and consumes the reagent. For GMP peptide resins, monomer batch records must demonstrate a negative Kaiser endpoint, HPLC purity ≥98.0 area%, and absence of free succinimide by TLC against a certified reference standard.

Amino Sugar Hydrochloride Protection Without Benzyl Chloroformate By-Product Profiles

D-Glucosamine hydrochloride is converted to N-Cbz-D-glucosamine in semi-synthetic aminoglycoside and glycopeptide intermediate routes where selective protection of the 2-amino group must precede esterification or glycosylation. The hydrochloride salt is neutralized in methanol/water 2:1 v/v using triethylamine at 0 °C, and Cbz-OSu is added in 1.00–1.05 equivalents relative to free amine to minimize bis-protection of the adjacent hydroxyl group. The reaction is held at 0–5 °C for 3 h, quenched with 1 mol/L hydrochloric acid to pH 2.0–2.5, concentrated under vacuum to remove methanol, and extracted with ethyl acetate. The organic phase is washed with 5% w/v sodium bicarbonate and then water, dried, and concentrated to a syrup that crystallizes from ethyl acetate/heptane.

Terminal N-Cbz-D-glucosamine is isolated as a white powder used in downstream glycosylation steps. Methanolic process streams carrying Cbz-OSu require ATEX-rated reactor zoning under Directive 2014/34/EU; nitrogen blanketing is applied to the reactor headspace because the wet crystalline reagent can release carbon dioxide and residual methanol vapor can form flammable headspace mixtures above 20 °C. EU import and registration obligations for this intermediate are governed by REACH (EC) No 1907/2006. For late-stage aminoglycoside intermediates, residual methanol is typically controlled to ≤3000 ppm and residual NHS to ≤0.5%. Published data for this specific amino sugar configuration is limited to pilot-scale reports; production-scale validation therefore requires design-space verification across at least three consecutive lots.

When Benzyl Chloroformate Is Replaced by the Succinimidyl Carbonate in Continuous Flow N-Protection for High-Hazard Intermediates

Continuous N-protection campaigns in high-hazard intermediate facilities integrate Cbz-OSu as a solid-feed carbonate source where benzyl chloroformate is disfavored due to phosgene-related impurity profiles and storage restrictions. In this configuration, an aqueous amino acid stream at 0.8 mol/L containing saturated sodium bicarbonate is combined with a 20–30% w/w solution of Cbz-OSu in THF in a static mixer at 0–10 °C. The biphasic mixture passes through a jacketed residence coil of 5.0 mm internal diameter and 20 m length with a residence time of 120–300 s under 25 kPa backpressure. The molar feed ratio of Cbz-OSu to free amine is set at 1.05–1.10, and in-line FTIR monitors the disappearance of the 1810 cm⁻¹ and 1750 cm⁻¹ succinimidyl carbonyl bands. The short residence time suppresses carbonate hydrolysis, which is the main yield-limiting side reaction in batch mode above 10 °C.

The terminal products from this flow process are N-Cbz-amino acid methyl esters and N-Cbz-amino acids intended for downstream peptide coupling. The flow reactor train is designed to ATEX requirements and the pressure-containing assembly is specified under PED 2014/68/EU. Continuous manufacturing validation is planned under ICH Q13, with design-space verification based on feed ratio, coil temperature, and residence time. A practical boundary is the low aqueous solubility of Cbz-OSu; the organic feed must be maintained above 15 °C to prevent precipitation in the dosing line, but the mixing zone must be cooled below 10 °C before the pH-rise zone becomes kinetically uncontrolled. Published data for this exact flow configuration is limited; process development therefore relies on DoE screening with in-line pH and FTIR rather than direct scale-up from fixed batch recipes.

During laboratory-scale preparation of amine-terminated poly(ethylene glycol) macroinitiators for N-carboxyanhydride block copolymerization, the terminal primary amine is converted to a benzyl carbamate with Cbz-OSu to prevent premature initiation or chain transfer during subsequent monomer activation. The PEG macroinitiator is dried by azeotropic distillation in toluene to ≤50 ppm water, then treated with 1.05 equivalents of Cbz-OSu in anhydrous dichloromethane at 0 °C for 12 h under argon. The by-product N-hydroxysuccinimide is removed by precipitation of the protected PEG into cold diethyl ether, and the terminal benzyl carbamate is removed later by hydrogenolysis over 10% Pd/C at 0.3 MPa hydrogen pressure in methanol. The protected macroinitiator must be stored under argon at -20 °C because the benzyl carbamate end group undergoes slow hydrolysis under ambient humidity above 60% RH. This application is predominantly research-grade; if the protected macroinitiator is transferred into a GMP polymer-drug conjugate route, ICH Q7 and FDA 21 CFR Part 211 controls apply to residual palladium and residual solvent levels.

Residual N-Hydroxysuccinimide Falls Below Release Limits Only After Countercurrent Washing of Cbz-Protected Peptide Isolates

Protected dipeptide and tripeptide fragments manufactured at kilogram scale retain N-hydroxysuccinimide in the crystallized solid unless the aqueous bicarbonate wash is operated as a countercurrent cascade rather than a single batch extraction. After the coupling step and acidification, the ethyl acetate phase containing the protected peptide is washed countercurrently with 5–8% w/v sodium bicarbonate at 35 °C through a 3-stage mixer-settler. The protected peptide is then crystallized from ethyl acetate/heptane, filtered, and dried at 35–40 °C under vacuum. Release testing includes ion chromatography for residual succinimide ≤0.1%, HPLC purity ≥99.0 area%, and residual palladium ≤10 ppm when hydrogenolysis is used in the subsequent Cbz removal step. The operational boundary for this downstream segment is the thermal lability of the benzyl carbamate: drying must remain below 45 °C, and aqueous washes above pH 9.5 are avoided because they promote premature decarboxylation of the protected peptide intermediate. Compliance for a protected peptide fragment classified as a drug intermediate follows FDA 21 CFR Part 211 for facility and quality unit oversight; if the fragment is supplied as an API starting material, ICH Q7 and ICH Q3A residual solvent limits apply to the final certification.